Astellas’s growth continues to be buoyed by prostate cancer treatment, Xtandi.
By Armando Uribe, Analytics Analyst
23 July 2016
Datamonitor Healthcare forecasts that Astellas’s prescription pharmaceutical sales will grow at a compound annual growth rate (CAGR) of 1.3%, reaching sales of $12.9bn by 2025. In the past, Astellas has focused primarily on urology and transplantation as its main Global Category Leaders. However, continued investment in its newest focus, oncology, will begin to pay dividends as the therapeutic area is projected to generate sales of $4.9bn by 2025 – making up 38% of the company’s overall sales. Prostate cancer treatment Xtandi (enzalutamide) will be Astellas’s largest growth driver and is forecast to reach $4.7bn in global sales by 2025.
As one of the company’s primary focus areas, Astellas remains committed to providing novel treatments for common genitourinary disorders. The company has built a strong presence in urology through the success of Flomax (tamsulosin; Boehringer Ingelheim/AbbVie/Astellas) and Vesicare (solifenacin succinate), as well as further solidifying its position in the market with the launch of Myrbetriq (mirabegron), the first beta-3 adrenergic agonist used for the treatment of overactive bladder. The continued growth of Myrbetriq in all major markets along with the uptake of two combination products will assist in mitigating sales declines for Flomax and Vesicare in the short term. Longer term, Astellas will struggle to counter declines to Vesicare due to the patent expirations of Myrbetriq starting in 2022 and disappointing Phase III results from the combination of solifenacin/mirabegron.
Astellas’s sales within its immunology and inflammation segment are forecast to fall at a CAGR of -6.5% over 2015−25, due to the decline of tacrolimus products Prograf, Astagraf XL, and the recent divestment of Protopic to LEO Pharma. All three products combined accounted for over $1.8bn in global sales in 2015; however, this total is forecast to drop to less than $1bn annually by 2020. The launch of in-licensed product Cimzia (certolizumab pegol; UCB) and pipeline treatment ASP015K in Japan for rheumatoid arthritis will not be enough to outweigh the impact of generic competition to these established portfolio leaders.
Datamonitor Healthcare’s company analysis on Astellas explores global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
Get your free demo of Datamonitor Healthcare today. Simply fill out the form to the right >>>